Impact News +++ Stifel upgrades DigitalOcean to Buy on AI demand, raises target to $160 (Investing.com) +++ DIGITALOCEAN Aktie +5,30%

REGENERON Aktie

>REGENERON Aktienkurs

588.5 EUR -0.6% (TradegateBSX)

Ask: 588.8 EUR / 110 Stück

Bid: 586.8 EUR / 110 Stück

Tagesumsatz: 6 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: +2,0%

1 Monat: +10,5%

3 Monate: -7,5%

6 Monate: -6,7%

1 Jahr: +25,1%

laufendes Jahr: -11,4%

>REGENERON Aktie

Profil:

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..

Insiderhandel:

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>REGENERON Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen, Rheuma- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

22.07.26 - 13:03	John Overton High School student receives Humane Science Award from National Anti-Vivisection Society (PR Newswire)
	Parker Nunnery one of five young scientists from across the world to receive $3,000 prize at 2026 Regeneron International Science and Engineering Fair NASHVILLE, Tenn., July 22, 2026 /PRNewswire/ -- Parker Nunnery, a 2026 John Overton High School graduate, was one of just five recipients......

22.07.26 - 01:09	Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
	SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......

21.07.26 - 16:12	The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN (PR Newswire)
	NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......

20.07.26 - 13:33	Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload (PR Newswire)
	Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered......

20.07.26 - 09:03	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
	LOS ANGELES, July 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

20.07.26 - 09:03	REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, July 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the......

17.07.26 - 16:06	REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (PR Newswire)
	SAN DIEGO, July 17, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that......

08.07.26 - 02:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 130030 USD (Insiderkauf)
	Ryan, Arthur F. - Aufsichtsrat - Tag der Transaktion: 2026-07-02...

07.07.26 - 19:45	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
	Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

07.07.26 - 16:18	Regeneron Pharmaceuticals Aktie: HSBC senkt Kursziel deutlich auf 800 USD - Therapeutika bleiben Favorit (Aktiencheck)
	London (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von HSBC: Die Analysten von HSBC haben das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 990 USD auf 800 USD gesenkt und das Rating "buy" bestätigt. [mehr]...

06.07.26 - 13:54	Regeneron Pharmaceuticals Aktie: Biotech-Chance oder Warnsignal? (Aktiencheck)
	New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Cantor Fitzgerald: Der Analyst Carter Gould vom Analysehaus Cantor Fitzgerald habe das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 785 auf 750 USD gesenkt und das Rating "overweight" bestätigt. [mehr]...

06.07.26 - 13:33	Regeneron expects Q2 pre-tax IPR&D charge of ~$127M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.26 - 17:30	Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

30.06.26 - 19:36	Hebel-Idee \| Long-Chance: Biotech-Aktien gehen steil – und hier gibt′s noch richtig was zu holen! (Wallstreet-Online)
	Unbemerkt von vielen Anlegerinnen und Anlegern vollzieht sich bei Biotech-Aktien eine steile Ausbruchsrallye. Mit viel Nachholpotenzial handelt jetzt Regeneron....

29.06.26 - 23:54	Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.06.26 - 20:54	Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities (CNBC)
	Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned....

28.06.26 - 02:24	This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested (Fool)
	Parabilis Medicines is ambitious, but it has Regeneron on its side already....

25.06.26 - 22:09	Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast (GlobeNewswire EN)
	TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day....

23.06.26 - 22:00	Regeneron′s Applications for gMG Drug Accepted by FDA and EMA (Zacks)
	Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule....

23.06.26 - 20:36	Regeneron myasthenia gravis therapy undergoes U.S. and EU review (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werde nie so reich an Geist, dass arm Du würdest am Herzen! - Otto Ludwig

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram